17,261 trials
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 10.4; 20.8 percentage of participants
Cancer
Primary: Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib — 509; 524; 259; 255 Nanograms per…
Head and Neck Neoplasms
Primary: Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates — 6.81; 18.18; 75.00 percentage of participants
Erythematotelangiectatic Rosacea
Primary: Response Rate for Achieving a 2 Grade Improvement on Clinician's Erythema Assessment (CEA) and Patient Self Assessment (PSA) Over 12 Hours After Dosing. — 17; 10; 7; 4…
Disorder Related to Renal Transplantation
Primary: Number of Participants With Acute Rejection (AR) of Transplant up to 6 Months Post Transplantation - Intent to Treat (ITT) Population — 4; 1; 1; 0 participants
Influenza Caused by the Novel Influenza A (H1N1) Virus
Primary: Haemagglutination Inhibition (HI) and Microneutralisation (MN) Antibody Titre Seroconversion Rate After the First Vaccination — 74.2; 81.5; 77.5; 75.6 percentage of…
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants With Seroconversion for Anti-pertussis Toxoid and Anti-filamentous Hemagglutinin Antibodies Post-vaccination With Either DTaP-IPV-Hep B-PRP~T…
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Confirmed Tumor Responses — 0; 0 participants
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage II Pancreatic Cancer
Primary: Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 21; 21 percentage of participants…
Asthma
Primary: Cmax of Budesonide After Administration of MAP0020 — 92.5; 175; 370 pg/ml
Influenza Caused by the Novel Influenza A (H1N1) Virus
Primary: Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination — 88.2; 97.3; 85.7; 91.9 percentage of participants
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: 6 Month Progression-free Survival (PFS) — 13 participants